Danaher Corporation to Acquire Phenomenex
By LabMedica International staff writers Posted on 14 Oct 2016 |
Danaher Corporation (Washington, D.C., USA) will acquire Phenomenex Inc., (Torrance, CA, USA), a privately held manufacturer and distributor of high-value consumables for the separation sciences, including proprietary chromatography consumables for the liquid and gas chromatography market.
Phenomenex has more than 7,000 products supporting various applications in drug discovery and development, clinical research, forensic toxicology, petrochemical, environmental analysis and food safety. Following the acquisition, it will operate as a standalone operating company, retaining the Phenomenex brand, its personnel and site locations.
“Phenomenex is a widely recognizable brand that we are proud to say is highly respected and well established as providing high-quality consumables to the scientific community worldwide,” said Fasha Mahjoor, CEO, Phenomenex. “Joining Danaher will allow us to maintain the high pace of innovation that our customers and international distributors have come to expect from us. This is our opportunity to further expand our R&D activities, benefit our customers with a more diversified product portfolio and reinforce our market leadership.”
“We are thrilled to have Phenomenex join Danaher’s life sciences portfolio of businesses, which include SCIEX, Beckman Coulter Life Sciences, Pall, Leica Microsystems and Molecular Devices,” said Dan Daniel, Executive Vice President, Danaher. “Phenomenex is a strong business characterized by high growth rates and margins and excellent growth prospects driven by increasing analytical testing needs in the health, research and environmental segments. The Danaher Business System (DBS) has a strong track record of helping businesses rapidly scale operations and create long-term customer value. We look forward to supporting the Phenomenex team in leveraging DBS tools for growth and welcoming them to our Life Sciences team.”
Related Links:
Danaher
Phenomenex
Phenomenex has more than 7,000 products supporting various applications in drug discovery and development, clinical research, forensic toxicology, petrochemical, environmental analysis and food safety. Following the acquisition, it will operate as a standalone operating company, retaining the Phenomenex brand, its personnel and site locations.
“Phenomenex is a widely recognizable brand that we are proud to say is highly respected and well established as providing high-quality consumables to the scientific community worldwide,” said Fasha Mahjoor, CEO, Phenomenex. “Joining Danaher will allow us to maintain the high pace of innovation that our customers and international distributors have come to expect from us. This is our opportunity to further expand our R&D activities, benefit our customers with a more diversified product portfolio and reinforce our market leadership.”
“We are thrilled to have Phenomenex join Danaher’s life sciences portfolio of businesses, which include SCIEX, Beckman Coulter Life Sciences, Pall, Leica Microsystems and Molecular Devices,” said Dan Daniel, Executive Vice President, Danaher. “Phenomenex is a strong business characterized by high growth rates and margins and excellent growth prospects driven by increasing analytical testing needs in the health, research and environmental segments. The Danaher Business System (DBS) has a strong track record of helping businesses rapidly scale operations and create long-term customer value. We look forward to supporting the Phenomenex team in leveraging DBS tools for growth and welcoming them to our Life Sciences team.”
Related Links:
Danaher
Phenomenex
Latest Industry News
- Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests
- CACLP 2025 New Date and Venue Announced
- Roche to Develop New Diagnostic Technologies for Traumatic Brain Injuries
- LGC Clinical Diagnostics and AccuGenomics Collaborate on Enhancing Cancer Testing Accuracy
- Beckman Coulter and SphingoTec Partner to Improve Kidney Health Assessment in Critical Care
- Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative
- Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance
- MEDICA LABMED FORUM 2024: International Experts Meet to Discuss Trending Topics in Laboratory Medicine
- Nova Biomedical and Terumo BCT Collaborate on Automated Cell Culture Sensing
- Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
- Roche Expands Digital Pathology Open Environment with Integration of Advanced AI Algorithms from New Collaborators
- Qiagen and Eli Lilly to Develop First QIAstat-Dx IVD Panel for Neurodegenerative Applications
- QIAGEN and AstraZeneca Expand Collaboration into New Disease Areas
- MEDICA 2024 + COMPAMED 2024: Adapted Hall Layout for Better Integration
- Global Coagulation Testing Driven by Increasing Blood Disorders and Surgical Interventions
- Sysmex and QIAGEN Expand Collaboration in Genetic Testing